Cabaletta Bio Inc
Research Cabaletta Bio Inc (CABA) on Bullrun: market cap USD 323.71M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCABA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 323.71M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 51.02M
- Free cash flow-USD 41.51M
Valuation Snapshot
latest market cap is USD 323.71M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 167.86M | -USD 132.31M | n/a | -2.1 | USD 82.98M | USD 27.10M | USD 112.05M |
| FY2024 | USD 0 | -USD 115.86M | -USD 90.43M | n/a | -2.34 | USD 163.96M | USD 15.60M | USD 152.34M |
| FY2023 | USD 0 | -USD 67.68M | -USD 54.24M | n/a | -1.65 | USD 193.24M | USD 5.02M | USD 236.20M |
| FY2022 | USD 0 | -USD 52.98M | -USD 48.83M | n/a | -1.81 | USD 81.61M | USD 5.14M | USD 104.52M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 323.71M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 220.05M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 115.19M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 972.68M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 269.55M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 109.63M | n/a | n/a | n/a |
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
Related stock research
Other Healthcare stocks
Aardvark Therapeutics Inc (AARD)
Abeona Therapeutics Inc (ABEO)
Acumen Pharmaceuticals Inc (ABOS)
Absci Corp (ABSI)
Arbutus Biopharma Corp (ABUS)
ABVC BioPharma Inc (ABVC)
Acadia Pharmaceuticals Inc (ACAD)
Adicet Bio Inc (ACET)
Achieve Life Sciences Inc (ACHV)
Alpha Cognition Inc (ACOG)
Aclaris Therapeutics Inc (ACRS)
Acrivon Therapeutics Inc (ACRV)
Frequently asked questions
What is Cabaletta Bio Inc's market cap?
Cabaletta Bio Inc's market capitalization is USD 323.71M.
What does Cabaletta Bio Inc do?
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.